NR
NeurAxis, Inc.
NRXS · AMEX
$5.75 +0.17% (+$0.01)
1M -8.60%
Market Cap $70.9M
P/E Ratio -
Div. Yield -
ROE 173.29%
Bulios Fair Price
$5.3
7.8% downside
Current Price
$5.75
Undervalued Fair Value Overvalued
According to Bulios Fair Price, NRXS is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
0 /100
Expensive P/S 13.33x
P/B 10.52x
P/E N/A
Growth
66 /100
Stable Rev. growth 9.96%
EPS growth N/A
FCF growth N/A
Profitability
20 /100
Weak Gross margin 85.56%
Net margin 148.04%
Op. margin 144.51%
Quality
7 /100
Poor ROIC 109.52%
ROE 173.29%
ROA 78.73%
Debt
69 /100
Low Debt/Equity 0.04x
Current ratio 3.04x
Int. coverage -145.93x
Stability
26 /100
Unstable Beta 1.45x
Rev. volatility 20.71%
EPS volatility 134.66%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about NRXS
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Brian Carrico
Employees
24
Headquarters
Carmel
Upcoming events
17 NOV
Earnings
Upcoming earnings report